Icon Group partners with SeeTreat to pioneer precision radiation therapy

In line with Icon’s commitment to exceptional patient care and innovation, Icon will be testing and validating Dose Review software at two Queensland locations – Icon Cancer Centre Toowoomba and Icon Cancer Centre Greenslopes. During the trial period, Icon and SeeTreat will work together to make the product suitable for widespread use once commercially released in early 2025.

SeeTreat CEO and Founder, Dr Trang Nguyen said Icon’s commitment to improving access to world-class cancer care aligns with SeeTreat’s vision and goals.

“Working with Icon has been an absolute pleasure, with both organisations clearly aligned and working toward the same goal of improving patient care. Professor Paul Keall and I founded SeeTreat to “turn the light on for cancer treatment, enabling the treatment team to see what we treat, and know whether the radiation is deposited as planned such that clinicians can course-correct as needed”.

Icon Group Executive Manager of Clinical Care, Trent Aland said this partnership reflects Icon’s ongoing commitment to investing in the latest technologies.

Dose Review* does not have TGA clearance and not available for sale in any market.

About SeeTreat 

SeeTreat is a software medical device start up that founded in 2023, led by Dr Trang Nguyen, Ms Antonia Dalton and Professor Paul Keall (Image X Institute, University of Sydney). The Founders are passionate to enable global access to their innovations rather than only a small number of patients accessing their software on clinical trials. SeeTreat’s headquarter is in Sydney, Australia, with 15 full time employees and rapidly growing.  Our first products are expected to be available to clinics in early to mid- 2025.

For more information visit https://www.seetreatmedical.com/ and follow SeeTreat Medical on LinkedIn at https://www.linkedin.com/company/seetreat-medical